Working… Menu

TAS-OX for Refractory Metastatic Colon Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02848079
Recruitment Status : Active, not recruiting
First Posted : July 28, 2016
Last Update Posted : March 2, 2020
Information provided by (Responsible Party):
Yale University

Brief Summary:
This study will examine the safety and effectiveness of oxaliplatin in combination with TAS-102 (TAS-OX) for treatment of patients with metastatic colorectal cancer whose cancer has progressed or recurred after FOLFOX chemotherapy.

Condition or disease Intervention/treatment Phase
Colorectal Neoplasms Drug: combined TAS-102 and TAS-OX Phase 1 Phase 2

Detailed Description:

TAS-102 is an oral agent, which consists of a combination of a novel antimetabolite 5-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI) that prevents degradation of FTD. It has demonstrated activity in chemorefractory metastatic colorectal cancer (mCRC) patients. In the Japanese randomized phase II trial, TAS-102 improved medial overall survival when compared to placebo (9.0 vs.6.6 months, Hazard Ratio (HR) 0.56) in patients with mCRC refractory to 5-fluorouracil (5-FU), irinotecan and oxaliplatin. Subsequently, a randomized phase III study conducted in 13 countries (RECOURSE trial) confirmed this benefit on overall survival when compared to placebo (7.1 months vs. 5.3 months, HR 0.68) in patients with refractory metastatic colorectal cancer (CRC) 5.

Oxaliplatin is a third generation platinum compound, which is active when used together with 5-FU in the treatment of mCRC (FOLFOX). FOLFOX chemotherapy, which is frequently combined with anti-angiogenic agent Bevacizumab, is widely accepted as the preferred first-line regimen in the treatment of this disease in the US. Oxaliplatin is also frequently reintroduced in more advanced settings. Reintroduction is seen after progression on maintenance therapy, after resolution of previous treatment limiting neuropathy, after disease recurrence post adjuvant treatment or post metastasectomy. In the control arm of a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer (OPTIMOX1 study), oxaliplatin was reintroduced in 27% of patients. Although patients derive clinical benefit when oxaliplatin is reintroduced, the response rates are not as robust as during initial exposures. Decreased efficacy may be at least in part due to prolonged exposure and resultant resistance to 5-FU, which is a backbone in maintenance and in oxaliplatin containing regimens. Hence, the investigators propose exploring the safety and efficacy of oxaliplatin in combination with an alternative anti-metabolite TAS-102 (TAS-OX).

TAS-102 has demonstrated activity in 5-FU refractory mCRC, so the investigators hypothesize that TAS-OX may serve as an alternative drug combination for patients who have progressed or recurred after FOLFOX, and who are candidates for additional oxaliplatin therapy.

This is a 2-part clinical trial with TAS-102 in combination with oxaliplatin. The first part will be a dose-finding run-in phase and will enroll 3-18 patients. The second part, the focus of this study, will be a single arm cohort , which will further evaluate the safety, as well as efficacy, of TAS-OX in the treatment of mCRC. The subjects in part 2 will be treated with the drug doses determined in Part 1 of the trial. Up to 50 patients will be enrolled in part 2. Anticipated enrollment may be as high as 68 patients. Maximum potential enrollment is listed under anticipated enrollment, below.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 68 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: TAS-102 and Oxaliplatin (TAS-OX) for Refractory Metastatic Colon Cancer
Study Start Date : August 2016
Estimated Primary Completion Date : July 1, 2020
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Oxaliplatin

Arm Intervention/treatment
Experimental: combined TAS-102 and oxaliplatin
Combination treatment with TAS-102 and oxaliplatin
Drug: combined TAS-102 and TAS-OX
Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.

Primary Outcome Measures :
  1. Overall Response Rate measured by Response Evaluation Criteria In Solid Tumor (RECIST) 1.1 criteria [ Time Frame: up to 30 days following discontinuation of treatment ]

Secondary Outcome Measures :
  1. Progression Free Survival assessed according to RECIST criteria version 1.1. [ Time Frame: from the date of start of treatment to the date of first documented progression or any cause of death assessed up to 12 months. ]
  2. Overall Survival assessed by time to death from start of study [ Time Frame: from the date of start of treatment to the date of any cause of death assessed up to 24 months. ]
  3. safety and tolerability assessed with Common Terminology Criteria for Adverse Events (CTCAE) [ Time Frame: assessed from start of treatment up to discontinuation of treatment or up to 12 months. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically confirmed stage IV colon cancer (AJCC 7th edition) that has progressed after standard therapy that included 5-FU, irinotecan and oxaliplatin. Patients who could not tolerate standard agents because of unacceptable, but reversible, toxicity necessitating their discontinuation will be allowed to participate.
  2. Patients who had received adjuvant chemotherapy and had recurrence during or within 6 months of completion of the adjuvant chemotherapy will be allowed to count the adjuvant therapy as one chemotherapy regimen.
  3. Progression of disease must be documented on the most recent scan.
  4. Presence of measurable disease (not required for Phase 1 portion of the trial).
  5. Retrovirus-associated DNA sequences (RAS) mutation and mismatch repair (MMR) status must be determined (or tissue availability for testing if not already determined)
  6. Age 18 years or older.
  7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  8. Life expectancy of at least 3 months.
  9. Patient with adequate organ function:

    1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
    2. Hemoglobin ≥ 9 g/dL
    3. Platelets (PLT) ≥ 75 x 109/L
    4. Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ≤ 5 x Upper limit of normal (ULN)
    5. Total serum bilirubin of ≤1.5 mg/dL (except for Grade 1 hyperbilirubinemia due solely to a medical diagnosis of Gilbert's syndrome).
    6. Albumin ≥ 2.5 g/dL
    7. Serum creatinine ≤ 1.5 x institutional ULN (Cockcroft and Gault formula)
  10. Adequate contraception if applicable.
  11. Women who are nursing must discontinue nursing prior to enrollment in the program.
  12. Ability to take oral medication (i.e. no feeding tube).
  13. Patient able and willing to comply with study procedures as per protocol.
  14. Patient able to understand and willing to sign and date the written voluntary informed consent form (ICF) at screening visit prior to any protocol-specific procedures.

Exclusion Criteria:

  1. Patients who have previously received TAS-102.
  2. Grade 2 or higher peripheral neuropathy.
  3. Symptomatic Central nervous system (CNS) metastases requiring treatment.
  4. Other active malignancy within the last 3 years (except for non-melanoma skin cancer or a non-invasive/in situ cancer).
  5. Pregnancy or breast feeding.
  6. Current therapy with other investigational agents.
  7. Active infection with body temperature ≥38°C due to infection.
  8. Major surgery within prior 4 weeks (the surgical incision should be fully healed prior to drug administration).
  9. Any anticancer therapy within prior 3 weeks of first dose of study drug.
  10. History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102.
  11. Current therapy with other investigational agents or participation in another clinical study or any investigational agent received within prior 4 weeks.
  12. Grade 3 or higher hypersensitivity reaction to oxaliplatin, or grade 1-2 hypersensitivity reaction to oxaliplatin not controlled with pre-medication.
  13. Unresolved toxicity of greater than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 attributed to any prior therapies (excluding anemia, alopecia, skin pigmentation, and platinum-induced neurotoxicity).
  14. Extended field radiation within prior 4 weeks of first dose of study drug or limited field radiation within prior 2 weeks of first dose of study drug.
  15. Psychological, familial, or sociological condition potentially hampering compliance with the study protocol and follow-up schedule.
  16. Involvement in the planning and/or conduct of the study.
  17. Previous enrollment in the present study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02848079

Layout table for location information
United States, Connecticut
Yale Cancer Center
New Haven, Connecticut, United States, 06510
Sponsors and Collaborators
Yale University
Layout table for investigator information
Principal Investigator: Jeremy S. Kortansky, M.D. Yale University
Layout table for additonal information
Responsible Party: Yale University Identifier: NCT02848079    
Other Study ID Numbers: 1605017852
First Posted: July 28, 2016    Key Record Dates
Last Update Posted: March 2, 2020
Last Verified: February 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases